ZBTB7A and hepatocellular carcinoma: After the initial report associating LRF/ZBTB7A with T cell lymphoblastic lymphoma/leukemia through the suppression of the Arf tumor suppressor (p19Arf) gene and the consequent decrease of p53 activity [38], accumulating evidence further show that LRF/ZBTB7A is overexpressed in several other human cancers, including non-small cell lung cancer (NSCLC) [40–43], hepatocellular carcinoma [44–48], prostate [49, 50], ovarian [51], breast [52–54] and gastric cancers [55], glioma [56], sarcomas [57, 58], colorectal cancer [59–62], and renal carcinoma [63].